RNA interference (RNAi) has been proved to be a powerful tool for gene knockdown purpose and holds great promise for the treatment of cancer. Our previous study demonstrated that the reduction of Ki-67 expression by means of chemically synthesized siRNAs and shRNAs expressed from plasmid resulted in proliferation inhibition in human renal carcinoma cells. In this study, we constructed a novel oncolytic adenovirus-based shRNA expression system, ZD55-Ki67, and explored ZD55-Ki67-mediated RNAi for Ki-67 gene silencing. Our results showed that ZD55-Ki67 could induce silencing of the Ki-67 gene effectively, allow for efficient tumor-specific viral replication and induce the apoptosis of tumor cells effectively in vitro and in nude mice. We conclude that combining shRNA gene therapy and oncolytic virotherapy can enhance antitumor efficacy as a result of synergism between CRAd oncolysis and shRNA antitumor responses.
Introduction
Ki-67 is a nuclear protein that is associated with cell proliferation. 1 Although the function of Ki-67 protein has not yet been elucidated, several facts suggest that the Ki-67 protein has an important role in the maintenance or regulation of the cell division cycle. 2 The Ki-67 antigen is known to accumulate from G1-phase to mitosis, where it is found at its highest content. The amount of the antigen decreases to a minimal level immediately after mitosis. 3 The Ki-67 protein is tightly regulated and depends on the proliferative status of the cell. Detailed cell cycle analysis revealed that the Ki-67 protein is present in nuclei of proliferating (G1, S, G2 phase and mitosis) cells but not in nuclei of quiescent cells (G0 phase). 4 Endl et al. 6 demonstrated that Ki-67 protein phosphorylation during mitosis is associated with condensation of the chromosomes and separation of sister chromatids 5 and required the presence of the cdc2 kinase and its regulatory subunit cyclinB. Many immunohistochemical analyses showed that Ki-67 is highly overexpressed in a number of cancer cases and that as an independent prognostic factor its expression levels were positively correlated with some clinicopathologic variables in patients. 7, 8 These observations indicated that Ki-67 may serve as a mediator of malignant behavior in cancer and suggested that the inhibitory effect of Ki-67 might be incorporated into novel cancer therapies. Kausch et al. 9 demonstrated that antisense-mediated inhibition of Ki-67 expression led to significant inhibition of proliferation and tumor growth in vitro and in vivo. On the basis of their findings, a clinical phase I study has been initiated where patients with bladder carcinoma are treated intravesically with antisense oligonucleotides targeting the Ki-67 gene.
RNA interference (RNAi) has been proved to be a powerful tool for gene knockdown purpose and holds great promise for the treatment of cancer. 10, 11 Initial investigations of RNA interference in cells relied on transfection of synthetic small interference RNA (siRNA) or plasmids designed to drive expression of short hairpin RNAs (shRNAs) through the use of RNA polymerase III promoters. 12, 13 This knockdown technology has been successfully applied to inhibit Ki-67 gene expression in renal cancer cell lines, but its utility is limited by the short half-life of siRNA and low transfection efficiency of plasmids.
Recently, an adenovirus vector using the RNA polymerase II cytomegalovirus (CMV) promoter has been developed for efficient delivery of shRNA into cancer cells and demonstrated to mediate gene silencing both in vitro and in vivo. 16 For safety reasons, however, adenovirus vectors employed in conventional cancer gene therapy are generally replication-deficient viruses, limiting the efficacy of gene transfer and duration of therapeutic gene expression. It is thus expected that the delivery of shRNAs using non-replicating vectors will exhibit similar difficulties. To solve this problem, adenovirus mutants that preferentially replicate in and lyse tumor cells, known as oncolytic adenoviruses, have been proposed as vectors. 17 These adenoviruses are capable of lysing tumor cells selectively, and more importantly, their selective replications will amplify not only themselves but also the carried therapeutic genes in tumor cells. 18 The most studied oncolytic adenovirus thus far, named ONYX-015, is an adenovirus with the E1B 55kDa gene deleted to attenuate viral replication and cytolysis in normal tissues but not in tumor cells. 19, 20 ONYX-015 has shown encouraging clinical outcome and safety in clinical trials. 21 To achieve an additional cytotoxic effect, ZD55, a new E1B 55kDa-deficient adenovirus that is similar to ONYX-015 but with a Bgl II cloning site to insert foreign therapeutic genes, was constructed by our collaborator Liu's laboratory. 22 ZD55 offers a new platform, for cancer gene therapy with a therapeutic gene that can be cloned into the restriction site if needed. Recently, ZD55, as the vector to transfer therapeutic gene XAF1 into the tumor cells (ZD55-XAF1), resulted in potent and specific cytopathic effect as well as high expression of XAF1 in tumor cell lines. More importantly, ZD55-XAF1 exhibited a superior suppression of tumor growth in an animal model of colorectal carcinoma in nude mice compared with a replication-defective counterpart. 23 However, there is no up to date report available about E1B 55kDa-deficient adenovirus-mediated RNAi in the therapy of cancer.
In this study, we constructed an oncolytic adenovirusbased shRNA expression system, ZD55-Ki67, and explored ZD55-Ki67-mediated RNAi for Ki67 gene silencing. We showed that ZD55-Ki67 could induce silencing of Ki-67 gene effectively, allow for efficient tumor-specific viral replication and induce the apoptosis of tumor cells effectively in vitro and in nude mice. We also demonstrated that tumor growth could be inhibited by nude mice using this system. These results indicate that ZD55-Ki67 can be used as a potential therapeutic strategy for treatment of cancer.
Materials and methods

Cell lines and culture conditions
The human renal carcinoma cell line 786-0 and ACHN were purchased from Shanghai Cell Collection (Shanghai, China) and Tongji University (Wuhan, China), respectively. Normal renal tube HK-2 cells were purchased from Cell Collection of Chinese Academy of Medical Sciences (Beijing, China). Human embryo kidney cells 293 (containing the E1 region of the adenovirus Ad) were purchased from Canada Microbix Biosystems Ltd. (ON, Canada). The HEK293 and HK-2 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS) (GIBCO-BRL, Gaithersburg, MD), 4 mM glutamine, 100 U ml À1 penicillin and 100 mg ml À1 streptomycin at 37 1C in a humidified atmosphere with 5% CO 2 . Cells (786-0 and ACHN) were routinely maintained in RPMI-1640 medium supplemented with 10% FBS, 100 U ml À1 penicillin and 100 mg ml
À1
streptomycin and 2 mM L-glutamine.
Virus construction and production pSilencerKi-67, an shRNA-expressing plasmid targeting the position 364-382 of human Ki-67 (GenBank accession No. NM_002417), was constructed in our laboratory. 15 pZD55, 22, 24 the E1B55kD-deleted oncolytic adenovirus construction plasmid, and pCA13, the E1-deleted adenovirus shuttle plasmid, were kindly provided by Professor Liu (Xin-Yuan Liu, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.). The Ki-67 siRNA expression cassette excised from pSilencerKi-67 was first subcloned into pCA13 to form pCA13-Ki-67. Then the expression cassette containing the Ki-67 shRNA controlled by the human CMV promoter was cut with Bgl II and subcloned into pZD55 to construct pZD55-Ki67. Oncolytic adenovirus ZD55-Ki67 and replication-defective adenovirus Ad-Ki67 were generated in HEK293 cells by homologous recombination between pCA13-Ki67 or pZD55-Ki67 and the adenovirus packaging plasmid pBHGE3 (Microbix Biosystems), respectively. ZD55-EGFP with reporter gene EGFP and AD55-EGFP (E1 region-deficient adenovirus carrying the gene of EGFP) were kindly provided by Professor XinYuan Liu. Large-scale purification of all adenoviruses was performed by ultracentrifugation with cesium chloride according to standard techniques. The titers were determined by plaque assay on HEK293 cells.
Cell viability assay
Cells were plated in 96-well plates and treated with various adenoviruses. At the indicated times, the medium was removed and fresh medium containing 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT, 0.5 mg ml
À1
) was added to each well. Cells were incubated at 37 1C for 4 h and then an equal volume of solubilization solution (0.01 N HCl in 10% SDS) was added to each well and mixed thoroughly. Absorbance from the plates was read on an ELX-800 spectrometer reader (Bio-Tek Instruments Inc., USA) at 570 nm.
Cytopathic assay 786-0 and ACHN tumor cell lines, as well as HK-2 cell line, were grown to subconfluence and infected with adenoviruses at various multiplicities of infection (MOI). At the end of each treatment, the medium was removed and washed twice. Crystal violet solution was added to the 24-well plate and incubated at room temperature for 15 min, then washed with distilled water and documented as photographs.
Quantitative real-time RT-PCR Real-time reverse transcriptase-PCR (RT-PCR) was carried out on cDNA by using the SYBR Green method with an ABI PRISM7700 sequence detection system. Total RNA was used as a template for cDNA synthesis. All reactions were carried out in a 25 ul 
Western blot analysis
Cells were harvested from the plates, and aliquots of cell extracts were separated on a 12% SDS-polyacrylamide gel. Then proteins were transferred to a nitrocellulose membrane and incubated overnight at 4 1C with the rabbit polyclonal antibody anti-Ad2 E1A (SC-403, Santa Cruz) or Ki-67 primary antibody (Santa Cruz), respectively. Membranes were then washed and incubated with alkaline phosphatase conjugated secondary antibodies in TBST for 2 h and developed using NBT/BCIP color substrate (Promega, Madison, USA). The density of the bands on the membrane were scanned and analyzed with an image analyzer.
Immunocytochemical staining
Cells were fixed with 4% paraformaldehyde onto glass coverslips. After washing with phosphate-buffered saline, the cells were incubated first with anti-Ki-67 primary antibody for 24 h and then with horseradish peroxidaseconjugated secondary antibody for 1 h. The Ki-67-positive staining was developed by diaminobezidin (DAB). For evaluation of Ki-67-positive fractions, at least 200 cells were counted in six different regions and the mean number was determined.
TdT-mediated dUTP-biotin nick end-labeling assay The TUNEL technique was performed to detect and quantitate apoptotic cell death using the in situ Cell Death Detection Kit (Roche, Indianapolis, IN) following the provider's instructions. Briefly, chamber slides were fixed with 4% paraformaldehyde and permeabilized in 0.1% Triton X-100. Then the slides were incubated with TUNEL reaction mixture for 1 h at 37 1C. After washing with PBS, the slides were incubated with peroxidaseconjugated antibody for 30 min at 37 1C and were developed with DAB system. Under microscopy, six fields were randomly selected from every sample and 100 cells were randomly selected from every field. The apoptotic rate ¼ (number of total apoptotic cells/ 100) Â 100%. 
Xenograft tumor model in nude mice animals
Immunohistochemistry staining
Tumors were harvested and fixed in 10% formalin, embedded in paraffin, and cut in 4 mm sections. Deparaffinized tumor sections were treated with 3% H 2 O 2 for 10 min to block the endogenous peroxidase and incubated with blocking serum (goat serum) at room temperature for 30 min. Immunohistochemistry was carried out with anti-Ki-67 primary antibody (Santa Cruz, USA) or anti-E1A (SC-403, Santa Cruz). After incubation with an anti-mouse secondary antibody, the expressions of Ki-67 or E1A were detected with diaminobenzidine (DAB; Sigma, St Louis, MO) by enhancement with an avidin-biotin reaction ABC kit (Vector Laboratories Burlingame, CA). Tissue sections stained without primary antibody served as negative control. The slides were then counterstained with hematoxylin. For evaluation of Ki-67-positive fractions, at least 200 cells were counted in six different regions and the mean number was determined.
Apoptotic cells in tumor tissue sections were quantified using the in situ apoptosis detection kit (Roche, Indianapolis, IN). Formalin-fixed, paraffin-embedded sections were dewaxed before being permeabilized with proteinase K for 15 minutes at room temperature. Endogenous peroxidase was blocked with 3% H 2 O 2 , and sections were incubated with equilibration buffer and terminal deoxynucleotidyl transferase (TdT) enzyme. Finally, the sections were incubated with antidigoxigenin-peroxidase conjugate. Peroxidase activity in each tissue section was shown by the application of DAB. Under microscopy, six fields were randomly selected from every sample and 100 cells were randomly selected from every field. The apoptotic rate ¼ (number of total apoptotic cells/ 100) Â 100%.
Laser-scanning confocal microscopy The tumor tissue was post-fixed overnight in paraformaldehyde before being transferred to 30% sucrose (in phosphate buffer) for 2-3 days and cut into 30 mm thick sections on a freezing microtome. After washing with 0.01 M phosphate-buffered saline (PBS), the sections were incubated first with 3% BSA in PBS containing 0.2% Triton X-100 for 30 min at 37 1C and then with the antiKi-67 or anti-E1A (1:200) in PBS containing 0.1% Triton X-100 overnight at 4 1C. The sections were washed three times for 10 min each in PBS containing 0.1% Triton X-100 at room temperature and incubated with FITCconjugated goat anti-rabbit IgG (1:150) for 4 h at room temperature. The sections were washed three times, mounted on glass slides, covered with coverslips, sealed with nail polish oil and stored at 4 1C. Fluorescent images were captured and analyzed on a laser-scanning confocal microscopy (LSM510, Carl Zeiss, Jena, Germany). The LSM510-related software was used to control the microscope and its settings.
Statistical analysis
Values were expressed as mean ± s.d., and statistical analysis of the results was carried out by one-way analysis of the variance (ANOVA) followed by Duncan's new multiple range method or Newman-Keuls test. P-valueso0.05 were considered significant.
Results
Construction and identification of ZD55-Ki67
Initially, a recombinant adenoviral vector named pZD55 was constructed by Liu, in which a fragment of E1B region from 2269-3327 was deleted and an oligonucleotide containing two stop codons and a Bgl II clone site were incorporated into this region. On the basis of this new vector, a recombinant adenovirus named ZD55-Ki67 was achieved by cloning the Ki-67 shRNA expression cassette containing the CMV promoter þ Ki-67 shRNA sequence into the Bgl II site. The schematic diagram of recombinant adenovirus ZD55-Ki67 is illustrated in Figure 1 . The successful construction of ZD55-Ki67 was confirmed by restrictive enzyme digestion assay and sequence assay, which showed that the Ki-67-shRNA sequence expression cassette cut from pCA13-Ki-67 using Bgl II was inserted into the corresponding site of pZD55 directly. The purified virus preparations were subjected to PCR and restriction digestion to confirm correct Figure 1 The schematic diagram of recombinant adenoviruses ZD55-Ki67 and Ad-Ki67. (a) In ZD55-Ki67, the E1B 55-kDa gene was replaced by the Ki67-shRNA sequence expression cassette. (b) Ad-Ki67 was generated in HEK293 cells by homologous recombination between pCA13-Ki67 and the adenovirus packaging plasmid pBHGE3. In Ad-Ki67, the E1 region was deficient and Ki67-shRNA was inserted into the corresponding site of the AD genome. To characterize this new adenovirus, we infected 786-0 and ACHN renal cancer cells with ZD55-Ki67, ZD55-EGFP, Ad-Ki67 and Ad-EGFP at an MOI 10 and examined the expression of E1A by western blot assay. As shown in Figure 2 , ZD55-Ki67 and ZD55-EGFP can express E1A protein whereas E1-deleted replicationdefective Ad-Ki67 and Ad-EGFP failed to express E1A protein.
Potent cytopathic effect induced by ZD55-Ki67
To explore whether Ki-67-shRNA could sensitize tumor cells to ZD55-triggered death, 786-0 and ACHN renal cancer cells were infected with ZD55-Ki67, ZD55-EGFP, Ad-Ki67 and Ad-EGFP at various MOIs as indicated. Cells were stained with crystal violet 7 days later. As shown in Figure 3 , marked cytopathic effect (CPE) was observed in both tumor cell lines infected with ZD55-Ki67 even at very low MOI, as compared with cells infected with ZD55-EGFP, Ad-EGFP or Ad-Ki67. The CPE of ZD55-Ki67 was more than 10 times greater than that of ZD55-EGFP and about 1000-fold greater than that of Ad-Ki67 (CPE could be detected only at MOI100) in tumor cells. It was notable that significant CPE was not observed in HK-2 cells for all these viruses. These results indicated that ZD55-Ki67 had selective CPE in tumor cells and inhibited the growth of tumor cells more effectively than Ad-Ki67 gene therapy or ZD55-EGFP virus therapy alone.
To further quantify the cytopathic effect of ZD55-Ki67, MTT assay was also performed to examine cell viability. Cells (786-0 and ACHN) were plated in 96-well plates and infected with ZD55-Ki67, ZD55-EGFP and Ad-Ki67 at different MOIs as indicated. As shown in Figure 4 , infection 786-0 and ACHN cells with ZD55-Ki67 resulted in a time-and dose-dependent CPE, and as was expected, ZD55-Ki67 could kill renal cancer cells more powerfully than Ad-Ki67 and ZD55-EGFP. These results indicated that Ki-67-shRNA strongly potentiated ZD55-induced cell death and that significant CPE could be achieved by combining Ki-67-shRNA with ZD55.
Inhibition of Ki67 gene expression by ZD55-Ki67 in vitro
To determine the effect of ZD55-Ki67 on Ki-67 expression, 786-0 and ACHN cells were infected with ZD55-Ki67, ZD55-EGFP, Ad-Ki67 and Ad-EGFP at an MOI of 10. Forty eight hours following infection, real time RT-PCR was performed to determine the level of endogenous Ki-67 mRNA expression. As shown in Figure 5a , both ZD55-Ki67 and Ad-Ki67 suppressed the expression of Ki-67 mRNA in cancer cells. In contrast, ZD55-EGFP and Ad-EGFP showed only a mild effect in reducing Ki-67 mRNA expression. We next assessed the effects of Ki-67 protein by western blotting and immunohistochemical analysis. Infection of cancer cells (786-0 and ACHN) with ZD55-Ki67 and Ad-Ki67 at an MOI of 10 resulted in a substantial loss of the Ki-67 protein and a similar downregulation of the Ki-67 expression, which is Effect of ZD55-Ki67 on tumor cell apoptosis TUNEL analysis indicated that, as shown in Figure 6 , 786-0 and ACHN cells infected with ZD55-Ki67 at an MOI of 10 showed a higher percentage of apoptosis cells (53 and 56%) than that of cancer cells infected with Ad-Ki67 (35 and 37%), ZD55-EGFP (22 and 25%) and Ad-EGFP(8.3 and 9.6%). The apoptotic rates of the control cells treated with PBS were only 5.5 and 5.7%, respectively.
Antitumor efficacy of ZD55-Ki67 in nude mice
On the basis of the in vitro data above, we investigated the effects of ZD55-Ki67 treatment on tumor growth in vivo. Cells (786-0) were injected subcutaneously into nude mice and four groups received ZD55-Ki67, ZD55-EGFP, AdKi67, Ad-EGFP and PBS intratumoral injection. After 9 weeks, all of the mice were killed and tumors were resected. In the control group receiving PBS, tumors displayed rapid and continued outgrowth during the course of the experiment, and the mean tumor size was 2496.021 mm 3 . The mean tumor size of the ZD55-Ki67 treatment group was 128.515 mm 3 , much smaller than that of the ZD55-EGFP treatment group (1133.37 mm ). Animals treated with ZD55-EGFP exhibited a statistically significant suppression of tumor development than Ad-Ki67 (Figure 7a and b) .
To verify that the therapeutic effect was because of inhibition of the Ki-67 gene and that ZD55-Ki67 can replicate in vivo, the tumors were frozen and used for immunohistochemical analysis of the Ki-67 antigen and E1A antigen. As shown in Figure 8 , Ki-67 staining showed a marked reduction of Ki-67-positive cells in the ZD55-Ki67 (37.7), Ad-Ki67 (67.1), ZD55-EGFP (102.8) and Ad-EGFP (127.1) treatment groups when compared 5) . Furthermore, the results demonstrated that ZD55-Ki67 suppressed the Ki-67 expression more potently than Ad-Ki67, whereas ZD55-EGFP and Ad-EGFP had only a mild effect in reducing Ki-67 expression than the PBS treatment. Moreover, as shown in Figure 9 , E1A expressions were detected in the ZD55-Ki67 and ZD55-EGFP treatment groups but not in Ad-Ki67 and Ad-EGFP treatment groups, which indicated that ZD55-Ki67 could replicate in tumor cells. These results were further proved by confocal microscopy.
Apoptotic cells in tumor sections were analyzed by TUNEL staining. TUNEL staining showed markedly more positive cells in the ZD55-Ki67 group (81.7 ± 5.8%), which were more significant than in the control groups with PBS (14.5±3.2%) and the other two treatment groups, for ZD55-EGFP(47.0±3.8)%, Ad-Ki67(62.7 ± 5.4)% and for Ad-EGFP (25.1 ± 2.1)% (Figure 10 ).
Discussion
Renal cell carcinoma (RCC) is the most frequent kidney malignance, and patients with metastatic disease have a poor prognosis. In 2006, 38 890 new cases of renal carcinoma in the United States, with an annual mortality of 12 840, were reported. 25 The tumor is considered to be relatively resistant to radiotherapy and chemotherapy, and only a minority of patients respond to a specific immunotherapy with interleukin-2 and interferon-a. 26 Despite intense efforts, a successful therapeutic regimen for metastatic RCC has not yet been established. Clearly, additional therapeutic modalities have to be explored in the quest for developing an effective therapy for metastatic RCC.
As RNAi possesses high specificity and high efficiency in downregulating gene expression, it was recently evaluated as a potential therapeutic strategy against human cancer.
27 It has been shown that the reduction of Ki-67 mRNA and protein, by means of chemically synthesized siRNAs and shRNAs expressed from plasmid, resulted in proliferation inhibition and apoptotic cell death in transfected human renal carcinoma cells, but the efficacy of RNAi targeting Ki-67 is not more pronounced. 14, 15 We wish to improve these results by using shRNA delivered by the adenoviral vector for a more effective, stable and long-term RNAi. Indeed, it has been proven that non-replicating adenoviral vectors expressing shRNAs could induce silencing of target genes in vitro and in vivo. 28, 29 However, as with any gene therapy approach, to be effective in cancer treatment, it is essential that these therapeutic shRNAs be delivered to most, if not all, cells of a tumor in vivo. Non-replicating adenoviral delivery systems have some disadvantages such as poor gene transfection efficiency, low anticancer gene expression and non-targeting to tumor cells. 30 In contrast, oncolytic adenovirus possesses intrinsic property to spread through a tumor mass, thus amplifying the input dose and extending the reach and duration of treatment. 31 These viruses may therefore be a more appropriate delivery for anticancer shRNAs.
As a successful paradigm of oncolytic adenovirus, ONYX-015, an E1B 55 kDa-deficient adenovirus, has proven to be effective against cancer cells both in vitro and in vivo experimental studies. 32, 33 The outcomes of clinical trials using ONYX-015 as monotherapy have been disappointing, however, revealing that the antitumor efficiency of this oncolytic adenovirus as a single agent is somehow limited and that further improvement on this oncolytic adenovirus would be needed to achieve better clinical response. 34, 35 Naturally, attempts to incorporate a therapeutic gene into ONYX-015 have augmented the antitumoral efficacy. 36 We hypothesize that the anticancer potency of oncolytic adenovirus might also be improved by arming with anticancer shRNAs. Therefore, we set out to design a platform for oncolytic viruses-mediated RNAi.
ZD55, a new E1B 55 kDa-deleted adenovirus vector, was engineered by our collaborator Liu's lab, which could specifically replicate and cause a significant cytopathic effect in all tumor cells tested. 22, 37 Liu had armed many therapeutic genes with ZD55 to construct a series of oncolytic adenoviruses, such as ZD55-IL-24, ZD55-TRAIL, ZD55-MnSOD and so on. All of those viruses showed potential antitumor activity and offered a novel platform for cancer gene therapy. 38, 39 To improve the antitumoral activity of Ki67-shRNA, we constructed an oncolytic virus RNAi-therapeutic system named ZD55-Ki67 with a Ki-67 shRNA expression cassette incorporated into the deficient E1B 55kDa region of ZD55. ZD55-Ki67 was identified with restriction enzyme digestion, PCR and sequence assay.
In a recent study, Carette and coworkers 40 first demonstrated that the oncolytic adenovirus AdD24E3, carrying a 24-bp deletion in the pRb-binding CR2 domain in E1A, can be used to deliver an shRNA to viralpermissive cancer cells. The shRNA-targeted luciferase was cloned into the E4 region of AdD24E3, which effectively silenced the luciferase gene transcript in viralpermissive A549 cells. However, they had not tested therapeutic genes in this system. Yoo et al. 17 introduced shRNA-targeting VEGF under the control of a U6 promoter in the E3 region of an E1A-mutated and E1B-deleted oncolytic adenovirus. Zhang et al. 41 constructed a system by cloning a K-ras-specific shRNA under the control of the H1 promoter into the deleted E3b region of ONYX-411. The antitumor outcomes through RNA silencing and oncolysis were ascertained in both studies. However, the unselective expression of the foreign U6 promoter or H1 promoter would make it difficult to limit the gene targeting to tumor cells.
In our present study, selective replication capability of ZD55-Ki67, similar to that of ZD55 with reporter gene EGFP (ZD55-EGFP), was demonstrated by E1A protein expression in renal cancer cells and in xenograft tumors. Significant cytopathic capacity was observed with crystal violet stain in both renal tumor cell lines infected with ZD55-Ki67, as compared with cells infected with ZD55-EGFP or Ad-Ki67. Moreover, the cytopathic capacity of ZD55-Ki67 was about 10 times greater than that of ZD55-EGFP, whereas the cytotoxicity of Ad-Ki67 is mild inspite of Ki-67 shRNA expression. For all these viruses, significant suppression of cell proliferation was not observed in normal renal tube HK-2 cells. In an MTT assay, the cytotoxic effect of ZD55-Ki67 on the cancer cell lines was more apparent than that of ZD55-EGFP or AdKi67. This cytopathic effect was time-and dosagedependent. No inhibitory effect was detected in HK-2 cells (data not shown). Apparently, ZD55-Ki67 achieved antitumoral efficacy much more superior to ZD55-EGFP, by inclusion of Ki-67 shRNA and superior to Ad-Ki67 by viral replication of ZD55. These results suggest that the incorporation of Ki-67 shRNA into the genome of ZD-55 does not disrupt its replication and selective killing effects in tumor cells and that ZD55-Ki67 inhibits the growth of tumor cells more effectively than ZD55-EGFP and Ad-Ki67.
In our present study, we demonstrated that shRNAs expressed from oncolytic adenoviruses ZD55-Ki67 specifically silence expression of a target gene in cancer cells. Ki-67 protein levels of ZD55-Ki67-treated 786-0 cells and Ad-Ki67-treated cells were reduced to 24 and 43% of the control group by calculating Ki67-positive cells. Interestingly, ZD55-EGFP also showed a mild effect in reducing Ki-67 mRNA expression whose mechanism remains to be determined. Moreover, in an indirect comparison, we observed that the maximal silencing efficiency in the context of Ad-Ki67 was similar to that induced by a plasmid encoding the same shRNA. These data indicated that oncolytic adenoviruses expressing shRNA could exert potential silencing efficiency and that viral replication would robustly amplify the copies of shRNA in tumor cells and allow the spread of viral infection to nearby tumor cells, which would further enhance the silencing potency.
Kausch et al. 42 targeted Ki-67 in human renal carcinoma cells with antisense oligonucleotides and showed that although Ki-67 protein was reduced, cells ZD55-Ki67 shRNA therapy for cancer J-N Zheng et al underwent apoptosis. Thus, they assumed that cancer cells entering mitosis in the absence of Ki-67 protein are unable to complete the process and are forced into apoptosis. Our data indicated that ZD55-Ki67 had much stronger apoptosis-induced activity in renal cancer cells than that induced by Ad-Ki67 or ZD55-EGFP. A possible explanation for the difference is that apart from the suppression of Ki-67, the infection of oncolytic adenovirus itself may act as a factor triggering the apoptosis pathway. For instance, the virus gene integration into the genomic DNA of cancer cells and the highlevel expression could lead to increased susceptibility to apoptosis. This explanation is supported by our data showing that ZD55-EGFP could induce the apoptosis of renal cancer cells, which was consistent with previous data obtained in other cancer cell lines. 37 Renal tumor cells could be killed efficiently by ZD55-Ki67 through apoptosis mediated by Ki-67 shRNA and cell death induced by viral replication. However, ZD55 with reporter gene EGFP (ZD55-EGFP) had less antitumor activity in vitro. Therefore, ZD55-Ki67 may become a new therapeutic agent for clinical cancer gene therapy.
Previous in vivo experiments 9 have shown that antisense treatment targeting Ki-67 of established subcutaneous renal tumors led to a significant inhibition of Ki-67 expression and tumor growth. Our research demonstrated that the potent antitumor activity of ZD55-Ki67 is more evident than that of ZD55-EGFP and Ad-Ki67 in renal and xenograft tumors. Moreover, in addition to its direct anticancer effect of oncolytic adenovirus, this strong antitumor activity of ZD55-Ki67 is because of more effective Ki-67-silencing effects and induction of tumor cell apoptosis of tumors. ZD55-Ki67 induced more effective and prolonged Ki-67-silencing effects in xenograft tumors than did Ad-Ki67. The lasting inhibition of the Ki-67 level was detected even 63 days after intratumoral injections of ZD55-Ki67.
These results highlight the potential of RNAi induced by oncolytic adenovirus for the treatment of cancers. Oncolytic adenovirus vectors could represent an efficient way to deliver therapeutic shRNAs directly into primary tumors in the near future in view of its potency and target specificity. As a delivery agent that couples shRNA expression with viral replication, oncolytic adenoviruses can minimize the impact of off-target activity in normal cells, and facilitate, sustain and regenerate shRNA expression within the tumor microenvironment. 43 The oncolytic adenovirus-shRNA construct also offers the advantage of enhancing shRNA-mediated antitumor response through its intrinsic oncolytic activity. However, lack of efficacy as the most obvious shortfall stands in the way of developing this platform into the mainstream of modern oncology practice. Clearly, extensive studies are still required to develop this platform. For example, the specificity and validity of the RNAi process, as seen for the Ki-67 translocation, allows for extending the repertoire of antitumor shRNAs for the treatment of cancer. Multiple therapeutic transgenes that can be expressed from a single oncolytic adenovirus with no loss of oncolytic activity 44 make it entirely feasible to deliver multiple siRNA payloads without exceeding the packaging capacity of the adenoviral genome. Currently, there is no new technology platform on the horizon that has more potential. The clinical need has not diminished, and should drive further development of oncolytic viralinduced RNAi therapies for cancer.
In conclusion, we constructed an armed oncolytic adenovirus system named ZD55-Ki67, which has both the lytic ability of oncolytic adenovirus and the capacity to deliver shRNA. The silence of the Ki-67 expression, by means of this adenoviral delivery approach, induces growth suppression and apoptosis in human renal cancer cell lines in vitro and inhibits human renal tumor growth in vivo in nude mice. Although the antitumor mechanism of Ki-67 silence has to be further elucidated for future use, our preliminary data indicate that Arming oncolytic adenovirus ZD55 with Ki-67 shRNA ZD55-Ki67 is an effective approach to enhance the antitumoral potency and provide a promising new treatment paradigm for renal cancer.
